These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 9294131)

  • 1. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.
    Mahata SK; O'Connor DT; Mahata M; Yoo SH; Taupenot L; Wu H; Gill BM; Parmer RJ
    J Clin Invest; 1997 Sep; 100(6):1623-33. PubMed ID: 9294131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity.
    Mahata SK; Mahata M; Wakade AR; O'Connor DT
    Mol Endocrinol; 2000 Oct; 14(10):1525-35. PubMed ID: 11043569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters.
    Mahapatra NR; Mahata M; Mahata SK; O'Connor DT
    J Hypertens; 2006 May; 24(5):895-904. PubMed ID: 16612252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses.
    Mahata SK; Mahata M; Wen G; Wong WB; Mahapatra NR; Hamilton BA; O'Connor DT
    Mol Pharmacol; 2004 Nov; 66(5):1180-91. PubMed ID: 15326220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance.
    Mahata SK; Mahata M; Parmer RJ; O'Connor DT
    J Biol Chem; 1999 Jan; 274(5):2920-8. PubMed ID: 9915830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the catecholamine release-inhibitory peptide catestatin (human chromogranin A(352-372)) with the chromaffin cell surface and Torpedo electroplax: implications for nicotinic cholinergic antagonism.
    Taupenot L; Mahata SK; Mahata M; Parmer RJ; O'Connor DT
    Regul Pept; 2000 Nov; 95(1-3):9-17. PubMed ID: 11062327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells.
    Lee JC; Taylor CV; Gaucher SP; Toneff T; Taupenot L; Yasothornsrikul S; Mahata SK; Sei C; Parmer RJ; Neveu JM; Lane WS; Gibson BW; O'Connor DT; Hook VY
    Biochemistry; 2003 Jun; 42(23):6938-46. PubMed ID: 12795588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A.
    Preece NE; Nguyen M; Mahata M; Mahata SK; Mahapatra NR; Tsigelny I; O'Connor DT
    Regul Pept; 2004 Apr; 118(1-2):75-87. PubMed ID: 14759560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel, catecholamine release-inhibitory peptide from chromogranin A: autocrine control of nicotinic cholinergic-stimulated exocytosis.
    Mahata SK; Mahata M; Yoo SH; Taupenot L; Wu H; Aroda VR; Livsey CV; Taulane JP; Goodman M; Parmer RJ; O'Connor DT
    Adv Pharmacol; 1998; 42():260-4. PubMed ID: 9327894
    [No Abstract]   [Full Text] [Related]  

  • 10. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP).
    Taupenot L; Mahata SK; Wu H; O'Connor DT
    J Clin Invest; 1998 Feb; 101(4):863-76. PubMed ID: 9466982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364). Properties and function.
    Mahata SK; Mahata M; Livsey Taylor CV; Taupenot L; Parmer RJ; O'Connor DT
    Adv Exp Med Biol; 2000; 482():263-77. PubMed ID: 11192587
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a beta-strand/loop/beta-strand structure secured by hydrophobic interactions and predictive of activity.
    Tsigelny I; Mahata SK; Taupenot L; Preece NE; Mahata M; Khan I; Parmer RJ; O'Connor DT
    Regul Pept; 1998 Oct; 77(1-3):43-53. PubMed ID: 9809795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin.
    Mahata SK; Mahapatra NR; Mahata M; Wang TC; Kennedy BP; Ziegler MG; O'Connor DT
    J Biol Chem; 2003 Aug; 278(34):32058-67. PubMed ID: 12799369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proadrenomedullin N-terminal 20 peptide: minimal active region to regulate nicotinic receptors.
    Mahata M; Mahata SK; Parmer RJ; O'Connor DT
    Hypertension; 1998 Nov; 32(5):907-16. PubMed ID: 9822452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulus coupling to transcription versus secretion in pheochromocytoma cells. Convergent and divergent signal transduction pathways and the crucial roles for route of cytosolic calcium entry and protein kinase C.
    Tang K; Wu H; Mahata SK; Mahata M; Gill BM; Parmer RJ; O'Connor DT
    J Clin Invest; 1997 Sep; 100(5):1180-92. PubMed ID: 9276735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogranin A: a surprising link between granule biogenesis and hypertension.
    Kim T; Loh YP
    J Clin Invest; 2005 Jul; 115(7):1711-3. PubMed ID: 16007250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromostatin, a 20-amino acid peptide derived from chromogranin A, inhibits chromaffin cell secretion.
    Galindo E; Rill A; Bader MF; Aunis D
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1426-30. PubMed ID: 1996343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulatory mechanism of the endogenous peptide catestatin on neuronal nicotinic acetylcholine receptors and exocytosis.
    Herrero CJ; Alés E; Pintado AJ; López MG; García-Palomero E; Mahata SK; O'Connor DT; García AG; Montiel C
    J Neurosci; 2002 Jan; 22(2):377-88. PubMed ID: 11784782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules.
    Taylor CV; Taupenot L; Mahata SK; Mahata M; Wu H; Yasothornsrikul S; Toneff T; Caporale C; Jiang Q; Parmer RJ; Hook VY; O'Connor DT
    J Biol Chem; 2000 Jul; 275(30):22905-15. PubMed ID: 10781584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The catecholamine release-inhibitory peptide catestatin (chromogranin A344-363) modulates myocardial function in fish.
    Imbrogno S; Garofalo F; Cerra MC; Mahata SK; Tota B
    J Exp Biol; 2010 Nov; 213(Pt 21):3636-43. PubMed ID: 20952611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.